Integral BioSciences (IBS) is a renowned organisation that offers a plethora of Integrated Drug Discovery Services for 14 years and counting. Our clientele comprises innovation-focused biotech start-ups and small to mid-sized pharmaceutical companies throughout the world. We assist them to accomplish their drug discovery objectives within a defined timeframe and budget. 

Our team of knowledgeable and experienced scientists along with the latest tools and techniques are the reasons we have become a prestigious name as a drug discovery contract research organization in India. If you are seeking a reliable drug discovery CRO, then you just need to connect with IBS once.

Drug discovery has to evolve constantly because there is a perpetual need to develop more efficient new drugs. Therefore, all the areas required to get compounds into the clinic are permanently changing.

As we offer a bouquet of chemistry and biol

Cancer is not just a name of a disease but a broad term for several diseases that affect various parts of the body distinctively such as lungs, liver, breast, brain, blood and stomach. It is quite a serious disease that is caused when cells in a certain tissue or organ of the body start abnormally and uncontrollably. The transformation of normal cells into tumour cells is a multistage process that involves continual unregulated proliferation of the cells, ultimately killing the normal cells that often leads to death. The tumour growth is prone to spread easily into neighbouring tissues and organs.

Cancer is counted as one of the leading causes of death worldwide, responsible for nearly 10 million deaths in 2020. Subsequently, the need for new and more efficient anticancer drugs with less toxicity has increased and that urge has led to remarkable growth in efforts of drug discovery for oncology. Drug discovery CROs are seeking new as well as

Small molecule drugs have been a prominent part of the drug discovery industry for over a century. Small molecule drugs are primarily organic compounds with a low molecular weight that include natural products and metabolites and they can be synthesized by drug discovery laboratories to specifically engage biological targets through different mechanisms. Also, distribution can further be manipulated and tailored.

Drug discovery CROs need to seek and rely on innovative approaches to overcome the challenges along the journey from initial hit-finding activities, through optimization of small molecules, up to the delivery of robust candidate drugs as the outcome for clinical evaluation. It can be said that the drug discovery of small molecules is quite sophisticated and challenging from target selection through to clinical evaluation but a rewarding area of drug discovery.

What Is Driving The Small Molecule Drug Discovery Ahead? Continue Reading

The drug discovery cycle comprises many kinds of phases and preclinical trial phases are one of the most significant phases. Preclinical studies, also known as preclinical development or nonclinical studies. As the term itself suggests, it includes those phases of the drug designing cycle which are done before clinical trials i.e; testing in humans.

The preclinical studies are done to understand the parallel between the real and the intended biological effect of a drug on an animal, primarily humans in order to predict the level of its efficacy. These trial phases enable the bioscientists to determine adverse events in people and to assess the risks to ensure safety.

Introduction to Preclinical Studies

Preclinical studies aid the drug discovery CROs to determine the feasibility and safety of drug compounds. There are certain tests that are iteratively done on laboratory animals to study the above-mentioned aspects of the respective dr

Cancer drugs that target gene abnormalities in tumours are one of the major preferences for CROs involved in drug discovery for oncology since the last few decades. Along with this approach, oncology oriented drug designing experts are also focusing on searching for molecular drivers of cancer and developing drugs to prevent them.

There has been a promising trend observed in oncology clinical pharmacology as the quest for new targeted cancer drugs not only consolidates the hopes for patients fighting cancer; it’s also creating more possibilities for pharmaceutical companies to yield benefit from the next wave of targeted oncology treatments.

Current Scenario of Immuno Oncology Agents

Until recent times, cancer treatments were mainly of four types as mentioned below.

1.  Surgery

2.  Radiotherapy Continue Reading

The World Health Organization lists cancer as the second leading cause of death across the globe. Drug discovery services consider oncology as one of the most prominent areas for new research. The human body grows new cells or allows existing cells to divide and form new ones as per its requirements. But sometimes this process can veer off the right path. The body starts creating new cells even when it does not need them or old cells do not die when they should. This leads to the formation of a tissue mass that can mutate into a tumor. The errant cells in malignant tumors do not necessarily follow an order while multiplying. Sometimes, they spread to other parts, from the organ where they originated.

Researchers are continuously exploring new treatments to address this abnormal growth effectively. Targeted cancer therapy is an approach t

It is a well-known fact that the process of drug discovery remarkably demands capital and time and both. In 2020, Indian Biotechnology was valued at around USD 70 billion and expected to reach the level of USD 150 billion by 2025. The overall amount spent in the biotechnology sector worldwide was USD 753.48 billion and expected to reach around USD 2.44 trillion by 2028. 

A big fraction of this amount is spent on R&D for drug discovery initiatives in the pharmaceutical and biotechnology sector. Still, only a small fraction of early-stage drug candidates were able to reach and pass the preclinical evaluation phase.

When a study was done for the assessment of terminated drug designing projects, the primary reasons for such a high rate of failure of drugs in clinical trials were found to be related to either one or more than one of the following factors, that are, pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties

Identifying new and better medicines for treating human diseases is a critical and time-consuming process. Drug discovery services companies are always experimenting to find new compounds with effective therapeutic qualities. But the long and complex process makes it necessary to accelerate the pace so that pharmaceutical companies can generate sufficient returns to sustain drug research and development.

Artificial Intelligence (AI) and Machine Learning (ML) are path-breaking technologies that are helping drug discovery organizations drive their digital transformations. AI-based tools are being applied to almost every stage of drug development to minimize time. Biological and chemical sources provide large volumes of complex information. Analyzing large and varied data sets is a time-consuming and tedious procedure. Applying machin

The invention of a new therapeutic is the result of the coalescence of various sets of expertise. Medicinal chemistry is a crucial discipline for all drug discovery services. Experts in the domain are needed to select and synthesize compounds that are crucial for establishing structure-activity relationships. Medicinal chemists are vital cogs in the wheel during the early stages of drug discovery. Their expertise helps in boosting efficiency and safety during pre-clinical animal testing. The role played by a chemist at a drug discovery incubator has evolved significantly over the years. In this article, we are discussing the role of medicinal chemistry in discovering new therapeutics. Let’s dive into the topic to know more.

What Is Medicinal Chemistry?

Medicinal chemistry encompasses the design, development, and synthesis of pharmaceuticals. More often than not, organic compounds are used as med

Healthcare systems across the globe require new drugs continuously. Drug discovery services play an important role in enabling the pharmaceutical industry to deliver new and better cures across multiple therapeutic areas. Drug discovery is the process used in medicine, biotechnology, and pharmacology to identify new candidate medications. Earlier medicinal cures were discovered either serendipitously or by determining the active element from traditional remedies. Modern drug discovery is based on the approach to understanding how a disease can be controlled at the molecular and physiological levels. Professionals and organizations involved in drug discovery use this understanding to determine disease-modifying elements (drug targets) that can be used to create remedies.

Here is a brief overview of the process used by drug discovery organizations.

1. Target Identification Continue Reading

During the past 40 years, the increase in computational power and the availability of chemo informatics data have allowed computational chemistry methods to become a vital tool for drug discovery services. Conventional drug discovery is a very time-consuming and costly process with a low turnover rate of druggable new chemical entities. It requires a collective effort of multiple disciplines to discover novel and effective drugs. In this direction, computer aided drug designing (CADD), involving various computational approaches assist in rationalizing the drug discovery and development process. It uses state-of-art technologies to improve the drug discovery workflow in a cost and time-effective manner. These technologies deliver possible therapeutic solutions by aligning chemical and biological spaces in drug discovery programs. It employs a variety of techniques viz. molecular d